A randomized phase III study of neoadjuvant chemotherapy followed by surgery versus surgery alone for patients with High Risk RetroPeritoneal Sarcoma (STRASS 2)

UVA Tracking #
Principal Investigator
Robert Dreicer
Contact Phone
Official Trial Title
EA7211: A Randomized Phase III Study of Neoadjuvant Chemotherapy followed by Surgery versus Surgery Alone for Patients with High Risk RetroPeritoneal Sarcoma (STRASS 2)
Study Description

The University of Virginia seeks adults ages 18 and over with histologically proven primary high risk leiomyosarcoma (LMS) or Liposarcoma (LPS) of retroperitoneal space or infra-peritoneal spaces of pelvis.

You will be randomized (assigned by chance) to the standard arm or the experimental arm.

• Standard arm: You will have surgery within 4 weeks following randomization
• Experimental arm: You will undergo 3 cycles of neoadjuvant (before surgery) chemotherapy starting within 2 weeks follow randomization

This study involves blood draw, physical examination, electrocardiogram (ECG), Computed Tomography (CT) scans, and surgery to remove your tumor.
Study-related procedures that are being done beyond your standard of care will be provided at no cost to you or your insurance.

Additional information can be found here: Study Details | Surgery With or Without Neoadjuvant Chemotherapy in High Risk RetroPeritoneal Sarcoma | ClinicalTrials.gov


No Compensation